{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:38:01Z","timestamp":1793644681936,"version":"4.5.1"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.euroneuro.2023.07.008","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T11:07:33Z","timestamp":1691147253000},"page":"23-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["The efficacy, safety, and adverse events of azapirones in anxiety disorders: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"76","author":[{"given":"Flavia","family":"Rossano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Caiazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4881-6004","authenticated-orcid":false,"given":"Nicolas","family":"Zotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Viacava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Irano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1749-2908","authenticated-orcid":false,"given":"Niccol\u00f2","family":"Solini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9202-9307","authenticated-orcid":false,"given":"Luca","family":"Pistone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Pezone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Cilmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2032-1181","authenticated-orcid":false,"given":"Michele","family":"De Prisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Iasevoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Solmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"de Bartolomeis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9647-0853","authenticated-orcid":false,"given":"Michele","family":"Fornaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2023.07.008_bib0001","unstructured":"Administration, U.F.a.D., 2016. FDA requires strong warnings for opioid analgesics, prescription opioid cough products, and benzodiazepine labeling related to serious risks and death from combined use, in: Release, F.N. (Ed.)."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0002","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11920-016-0727-9","article-title":"Benzodiazepine Misuse in the Elderly: risk Factors, Consequences, and Management","volume":"18","author":"Airagnes","year":"2016","journal-title":"Curr. Psych. Rep"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0003","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.biopsych.2009.03.012","article-title":"The serotonin-1A receptor in anxiety disorders","volume":"66","author":"Akimova","year":"2009","journal-title":"Biol. Psych."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0004","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jad.2014.11.056","article-title":"Autonomic arousal in childhood anxiety disorders: associations with state anxiety and social anxiety disorder","volume":"175","author":"Alkozei","year":"2015","journal-title":"J. Affect. Disord"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000119464","article-title":"Controlled comparison of buspirone and oxazepam in generalized anxiety","volume":"24","author":"Ansseau","year":"1990","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0006","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10484-022-09548-0","article-title":"Autonomic Dysregulation in Child Social Anxiety Disorder: an Experimental Design Using CBT Treatment","volume":"47","author":"Asbrand","year":"2022","journal-title":"Appl. Psychophysiol. Biofeedback"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0007","doi-asserted-by":"crossref","first-page":"31s","DOI":"10.1097\/00004714-199006001-00007","article-title":"Abuse potential of buspirone and related drugs","volume":"10","author":"Balster","year":"1990","journal-title":"J. Clin. Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0008","doi-asserted-by":"crossref","first-page":"327","DOI":"10.31887\/DCNS.2015.17.3\/bbandelow","article-title":"Epidemiology of anxiety disorders in the 21st century","volume":"17","author":"Bandelow","year":"2015","journal-title":"Dialogues. Clin. Neurosci"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0009","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00023210-200418010-00004","article-title":"Cognitive effects of long-term benzodiazepine use: a meta-analysis","volume":"18","author":"Barker","year":"2004","journal-title":"CNS. Drugs"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0010","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0028-3908(99)00010-6","article-title":"A review of central 5-HT receptors and their function","volume":"38","author":"Barnes","year":"1999","journal-title":"Neuropharmacology"},{"issue":"Suppl 4","key":"10.1016\/j.euroneuro.2023.07.008_bib0011","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1078\/1433-187X-00309","article-title":"Kava-Kava extract LI 150 is as effective as Opipramol and Buspirone in Generalised Anxiety Disorder\u2013an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients","volume":"10","author":"Boerner","year":"2003","journal-title":"Phytomedicine"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0012","doi-asserted-by":"crossref","first-page":"47s","DOI":"10.1097\/00004714-199006001-00010","article-title":"Buspirone therapy in anxious elderly patients: a controlled clinical trial","volume":"10","author":"B\u00f6hm","year":"1990","journal-title":"J. Clin. Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0013","first-page":"112","article-title":"Double-blind, randomized clinical evaluation of buspirone and diazepam in generalized anxiety disorders","volume":"6","author":"Boral","year":"1989","journal-title":"Adv. Ther"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0014","first-page":"207","article-title":"Efficacy and safety of a putative anxiolytic agent: ipsapirone","volume":"26","author":"Borison","year":"1990","journal-title":"Psychopharmacol. Bull"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0015","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0278-5846(95)00102-2","article-title":"Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam","volume":"19","author":"Bourin","year":"1995","journal-title":"Prog. Neuropsychopharmacol. Biol. Psych."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0016","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00004850-199300830-00006","article-title":"A placebo-controlled double-blind multicenter trial of two doses of ipsapirone versus diazepam in generalized anxiety disorder","volume":"8","author":"Boyer","year":"1993","journal-title":"Int. Clin. Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0017","article-title":"Benzodiazepines versus placebo for panic disorder in adults","volume":"3","author":"Breilmann","year":"2019","journal-title":"Cochrane. Database. Syst. Rev"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0018","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jrsm.57","article-title":"Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions","volume":"3","author":"Chaimani","year":"2012","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0019","first-page":"1084","article-title":"Comparison of the efficacy of trazodone, tandospirone and alprazolam in the treatment of patients with generalized anxiety","volume":"15","author":"Chen","year":"2006","journal-title":"Chinese. Journal. of. Behavioral. Medicine. and. Brain. Science"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0020","first-page":"43","article-title":"A randomized controlled study of buspirone and valium in the treatment of general anxiety disorder","volume":"31","author":"Chen","year":"1998","journal-title":"Chinese. Journal. of. Psych."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0021","first-page":"4938","article-title":"Tandospirone and clonazepam in the treatment of generalized anxiety disorder","volume":"16","author":"Chen","year":"2007","journal-title":"Xiandai. Zhongxiyi. Jiehe. Zazhi"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0022","first-page":"65","article-title":"Effect comparison of Tandospirone and Escitalopram in generalized anxiety disorder","volume":"13","author":"Cheng","year":"2018","journal-title":"China. Journal. of. Pharmaceutical. Economics"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0023","article-title":"Azapirones for generalized anxiety disorder","volume":"2006","author":"Chessick","year":"2006","journal-title":"Cochrane. Database. Syst. Rev"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0024","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1176\/ajp.148.5.598","article-title":"The assessment and treatment of performance anxiety in musicians","volume":"148","author":"Clark","year":"1991","journal-title":"Am. J. Psych."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0002-9343(86)90326-8","article-title":"Double-blind comparison of buspirone and clorazepate in anxious outpatients","volume":"80","author":"Cohn","year":"1986","journal-title":"Am. J. Med"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0026","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1185\/03007998909115213","article-title":"A pooled, double-blind comparison of the effects of buspirone, diazepam and placebo in women with chronic anxiety","volume":"11","author":"Cohn","year":"1989","journal-title":"Curr. Med. Res. Opin"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0027","first-page":"409","article-title":"Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double-blind study","volume":"47","author":"Cohn","year":"1986","journal-title":"J. Clin. Psych."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0028","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/0278-5846(94)90003-5","article-title":"A phase II multicenter dose-finding, efficacy and safety trial of ipsapirone in outpatients with generalized anxiety disorder","volume":"18","author":"Cutler","year":"1994","journal-title":"Prog. Neuropsychopharmacol. Biol. Psych."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0029","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/00004714-199312000-00009","article-title":"A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial","volume":"13","author":"Cutler","year":"1993","journal-title":"J. Clin. Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0030","first-page":"241","article-title":"Clinical observation of Buspirone and Diazepam in the treatment of Generalized anxiety disorder","volume":"8","author":"Dai","year":"1995","journal-title":"Sichuan. Mental. Health"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0031","doi-asserted-by":"crossref","first-page":"528","DOI":"10.4088\/JCP.v60n0805","article-title":"Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder","volume":"60","author":"Davidson","year":"1999","journal-title":"J. Clin. Psych."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0032","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00004714-199502000-00003","article-title":"Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study","volume":"15","author":"Delle Chiaie","year":"1995","journal-title":"J. Clin. Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0033","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4088\/JCP.v61n0203","article-title":"Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder","volume":"61","author":"DeMartinis","year":"2000","journal-title":"J. Clin. Psych."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0034","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3390\/neurolint13040059","article-title":"Benzodiazepines: uses, Dangers, and Clinical Considerations","volume":"13","author":"Edinoff","year":"2021","journal-title":"Neurol. Int"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0035","doi-asserted-by":"crossref","first-page":"2s","DOI":"10.1097\/00004714-199006001-00002","article-title":"Azapirones: history of development","volume":"10","author":"Eison","year":"1990","journal-title":"J. Clin. Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0036","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/BF02244440","article-title":"Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder","volume":"105","author":"Enkelmann","year":"1991","journal-title":"Psychopharmacology. (Berl)"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0037","first-page":"751","article-title":"Double-blind comparison of buspirone with diazepam in anxious patients","volume":"41","author":"Fabre","year":"1987","journal-title":"Curr. Ther. Res. Clin. Exp"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0038","first-page":"28","article-title":"Clinical evaluation of tandospirone citrate and paroxetine hydrochloride in the treatment of generalized anxiety","volume":"36","author":"Fan","year":"2020","journal-title":"Chinese. Community. Doctors"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0039","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000118565","article-title":"Analysis of individual symptoms in generalized anxiety\u2013a pooled, multistudy, double-blind evaluation of buspirone","volume":"21","author":"Feighner","year":"1989","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0040","first-page":"103","article-title":"A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder","volume":"43","author":"Feighner","year":"1982","journal-title":"J. Clin. Psych."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0041","first-page":"1159","article-title":"Efficacy of Tandospirone and Citalopram in the Treatment of Generalized Anxiety Disorder","volume":"21","author":"Gao","year":"2013","journal-title":"J. Health. Psychol"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0042","article-title":"Pharmacotherapy of Anxiety Disorders: current and Emerging Treatment Options","volume":"11","author":"Garakani","year":"2020","journal-title":"Front. Psych."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0043","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.resp.2010.04.024","article-title":"The locus coeruleus and central chemosensitivity","volume":"173","author":"Gargaglioni","year":"2010","journal-title":"Respir. Physiol. Neurobiol"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0044","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1176\/appi.ajp.157.4.493","article-title":"Neuroanatomical hypothesis of panic disorder, revised","volume":"157","author":"Gorman","year":"2000","journal-title":"Am. J. Psych."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0045","first-page":"13","article-title":"A Comparative Study of Tandospirone and Mirtazapine in the treatment of generalized Anxiety Disorder","volume":"22","author":"Guo","year":"2010","journal-title":"Journal. of. Heze. Medical. College"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0046","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychol."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0047","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1749-6632.1990.tb16877.x","article-title":"The Central 5-HT1A Receptors: pharmacological, Biochemical, Functional, and Regulatory Properties a","volume":"600","author":"Hamon","year":"1990","journal-title":"Ann. N. Y. Acad. Sci"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0048","first-page":"154","article-title":"Clinical profile of gepirone, a nonbenzodiazepine anxiolytic","volume":"24","author":"Harto","year":"1988","journal-title":"Psychopharmacol. Bull"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0049","doi-asserted-by":"crossref","first-page":"15049","DOI":"10.1073\/pnas.95.25.15049","article-title":"Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice","volume":"95","author":"Heisler","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0050","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022)","author":"Higgins","year":"2022"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0051","series-title":"Cochrane Handbook For Systematic Reviews of Interventions Version 6.3 (updated February 2022)","author":"Higgins","year":"2022"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0052","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/hup.2361","article-title":"Clinical evaluation of the efficacy and safety of tandospirone versus sertraline monotherapy for social anxiety disorder: a randomized open-label trial","volume":"28","author":"Huang","year":"2013","journal-title":"Hum. Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0053","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010828.pub2","article-title":"Azapirones versus placebo for panic disorder in adults","author":"Imai","year":"2014","journal-title":"Cochrane. Database. Syst. Rev"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0054","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/j.1875-9114.1985.tb03430.x","article-title":"Comparison of buspirone and diazepam in generalized anxiety disorder","volume":"5","author":"Jacobson","year":"1985","journal-title":"Pharmacotherapy"},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2023.07.008_bib0055","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","article-title":"Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders","volume":"14","author":"Katzman","year":"2014","journal-title":"BMC. Psych."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0056","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/archpsyc.1993.01820160076009","article-title":"False suffocation alarms, spontaneous panics, and related conditions. An integrative hypothesis","volume":"50","author":"Klein","year":"1993","journal-title":"Arch. Gen. Psych."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0057","first-page":"433","article-title":"A double-blind comparison study of buspirone and alprazolam: evaluation of efficacious and tolerability in outpatients with anxiety","volume":"43","author":"Knijnik","year":"1994","journal-title":"J. Bras. Psiquiatr"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0058","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s002130050578","article-title":"Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients","volume":"136","author":"Laakmann","year":"1998","journal-title":"Psychopharmacology. (Berl)"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0059","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00004714-198702000-00003","article-title":"A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms","volume":"7","author":"Lader","year":"1987","journal-title":"J. Clin. Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0060","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s002130050731","article-title":"A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder","volume":"139","author":"Lader","year":"1998","journal-title":"Psychopharmacology. (Berl)"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0061","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/j.1526-4610.2005.05181.x","article-title":"Efficacy of the 5-HT1A agonist, buspirone hydrochloride, in migraineurs with anxiety: a randomized, prospective, parallel group, double-blind, placebo-controlled study","volume":"45","author":"Lee","year":"2005","journal-title":"Headache"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0062","first-page":"461","article-title":"[Efficacy and withdrawal of clobazam, lorazepam and buspirone in the treatment of anxiety disorders]","volume":"22","author":"Lemoine","year":"1996","journal-title":"Encephale"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0063","first-page":"34","article-title":"A clinical controlled study of tandospirone and alprazolam in the treatment of generalized anxiety disorder","volume":"26","author":"Li","year":"2010","journal-title":"Chinese. Community. Doctors"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0064","first-page":"3773","article-title":"A comparative study of paroxetine and tandospirone in the treatment of generalized anxiety disorder","volume":"27","author":"Li","year":"2011","journal-title":"The. Journal. of. Practical. Medicine"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0065","first-page":"55","article-title":"A comparative study of tandospirone citrate and paroxetine hydrochloride in the treatment of generalized anxiety","volume":"14","author":"Li","year":"2012","journal-title":"Chinese. Community. Doctors"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0066","first-page":"48","article-title":"Efficacy analysis of tandospirone and clonazepam in the treatment of generalized anxiety disorder","volume":"12","author":"Li","year":"2014","journal-title":"Guide. of. China. Medicine"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0067","first-page":"495","article-title":"A comparative study between mirtazapine and buspirone in the treatment of generalized anxiety disorder","volume":"17","author":"Liu","year":"2005","journal-title":"Medical. Journal. of. Chinese. People's. Health"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0068","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.pnpbp.2004.06.007","article-title":"Interactions between anxiety, social support, health status and buspirone efficacy in elderly patients","volume":"28","author":"Majercsik","year":"2004","journal-title":"Prog. Neuropsychopharmacol. Biol. Psych."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0069","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.pnpbp.2003.09.013","article-title":"The effect of social factors on the anxiolytic efficacy of buspirone in male rats, male mice, and men","volume":"27","author":"Majercsik","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psych."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0070","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1177\/0269881107077355","article-title":"Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials","volume":"21","author":"Martin","year":"2007","journal-title":"J. Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0071","first-page":"551","article-title":"Comparison of efficacy of tandospirone and alprazolam in the treatment of anxiety disorder","volume":"22","author":"Meng","year":"2010","journal-title":"Medical. Journal. of. Chinese. People's. Health"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0072","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1440-1819.2009.02055.x","article-title":"Randomized, single-blind, trial of sertraline and buspirone for treatment of elderly patients with generalized anxiety disorder","volume":"64","author":"Mokhber","year":"2010","journal-title":"Psych. Clin. Neurosci"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0073","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/026988119500900407","article-title":"Buspirone treatment as an aid to benzodiazepine withdrawal","volume":"9","author":"Morton","year":"1995","journal-title":"J. Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0074","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1192\/bjp.154.4.529","article-title":"Comparative assessment of efficacy and withdrawal symptoms after 6 and 12 weeks' treatment with diazepam or buspirone","volume":"154","author":"Murphy","year":"1989","journal-title":"Br. J. Psych."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0075","series-title":"Generalised Anxiety Disorder and Panic Disorder in adults: Management","year":"2011"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0076","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1176\/appi.ps.55.3.233","article-title":"Practical Geriatrics: use of Benzodiazepines Among Elderly Patients","volume":"55","author":"Olivera J. Bogunovic","year":"2004","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0077","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/jrsm.1053","article-title":"GOSH\u2013a graphical display of study heterogeneity","volume":"3","author":"Olkin","year":"2012","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0078","unstructured":"Organization, W.H., 2023. Guidelines for ATC classification and DDD assignment."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0079","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0080","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/0278-5846(85)90032-6","article-title":"Buspirone: anxiolytic?","volume":"9","author":"Pecknold","year":"1985","journal-title":"Prog. Neuropsychopharmacol. Biol. Psych."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0081","first-page":"766","article-title":"Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo","volume":"34","author":"Pecknold","year":"1989","journal-title":"Can. J. Psych."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0082","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.0924-2708.2004.0080.x","article-title":"Panic disorder: from respiration to the homeostatic brain","volume":"16","author":"Perna","year":"2004","journal-title":"Acta. Neuropsychiatr."},{"issue":"Suppl","key":"10.1016\/j.euroneuro.2023.07.008_bib0083","first-page":"31","article-title":"Treatment of generalized anxiety disorder: preliminary clinical experience with buspirone","volume":"51","author":"Petracca","year":"1990","journal-title":"J. Clin. Psych."},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2023.07.008_bib0084","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000284627","article-title":"Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone","volume":"22","author":"Pohl","year":"1989","journal-title":"Psychopathology"},{"issue":"Suppl 11","key":"10.1016\/j.euroneuro.2023.07.008_bib0085","first-page":"19","article-title":"Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone","volume":"58","author":"Pollack","year":"1997","journal-title":"J. Clin. Psych."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0086","doi-asserted-by":"crossref","first-page":"14476","DOI":"10.1073\/pnas.95.24.14476","article-title":"Serotonin receptor 1A knockout: an animal model of anxiety-related disorder","volume":"95","author":"Ramboz","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0087","first-page":"502","article-title":"Comparative clinical evaluation of buspirone and diazepam in generalized anxiety disorders","volume":"47","author":"Ramchandran","year":"1990","journal-title":"Curr. Ther. Res. Clin. Exp"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0088","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1001\/archpsyc.1988.01800290060008","article-title":"Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone","volume":"45","author":"Rickels","year":"1988","journal-title":"Arch. Gen. Psych."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0089","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00004714-199708000-00006","article-title":"Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial","volume":"17","author":"Rickels","year":"1997","journal-title":"J. Clin. Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0090","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of random effects meta-analyses","volume":"342","author":"Riley","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0091","series-title":"WebPlotDigitizer","author":"Rohatgi","year":"2017"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0092","first-page":"351","article-title":"A clinical trial of buspirone and diazepam in the treatment of generalized anxiety disorder","volume":"32","author":"Ross","year":"1987","journal-title":"Can. J. Psych."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0093","first-page":"545","article-title":"[Buspirone in the treatment of Generalized Anxiety Disorders]","volume":"27","author":"Rzewuska","year":"1993","journal-title":"Psychiatr. Pol"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0094","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/hup.470090604","article-title":"Overlap of buspirone with lorazepam, diazepam and bromazepam in patients with generalized anxiety disorder: findings from a controlled, multicentre, double-blind study","volume":"9","author":"Sacchetti","year":"1994","journal-title":"Hum. Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0095","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0014-2999(82)90406-X","article-title":"Buspirone, a non-benzodiazepine anxiolytic, increases locus coeruleus noradrenergic neuronal activity","volume":"86","author":"Sanghera","year":"1982","journal-title":"Eur. J. Pharmacol"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0096","doi-asserted-by":"crossref","first-page":"120","DOI":"10.9740\/mhc.2016.05.120","article-title":"Benzodiazepine use, misuse, and abuse: a review","volume":"6","author":"Schmitz","year":"2016","journal-title":"Ment. Health. Clin"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0097","unstructured":"Sch\u00fcnemann, H., Bro\u017cek, J., Guyatt, G., Oxman, A., editors, 2013. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated October 2013."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0098","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00004714-198808000-00033","article-title":"Buspirone in the treatment of panic disorder: a controlled pilot comparison with clorazepate","volume":"8","author":"Schweizer","year":"1988","journal-title":"J. Clin. Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0099","first-page":"166","article-title":"A controlled double blind clinical trial of buspirone and diazepam in generalised anxiety disorder","volume":"32","author":"Shah","year":"1990","journal-title":"Indian. J. Psych."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1993.tb03405.x","article-title":"The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study","volume":"88","author":"Sheehan","year":"1993","journal-title":"Acta. Psychiatr. Scand"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0101","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00004714-199002000-00002","article-title":"Is buspirone effective for panic disorder?","volume":"10","author":"Sheehan","year":"1990","journal-title":"J. Clin. Psychopharmacol"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0102","first-page":"269","article-title":"Clinical comparative observation of tandospirone and alprazolam in the treatment of generalized anxiety disorder","volume":"37","author":"Song","year":"2013","journal-title":"Hei. Long. Jiang. Med. J."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0103","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ajodo.2019.12.011","article-title":"Prediction interval in random-effects meta-analysis","volume":"157","author":"Spineli","year":"2020","journal-title":"Am. J. Orthod. Dentofacial. Orthop."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0104","first-page":"287","article-title":"Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms","volume":"57","author":"Sramek","year":"1996","journal-title":"J. Clin. Psych."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0105","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0106","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1176\/appi.ajp.158.8.1326","article-title":"Inverse relationship between serotonin 5-HT1A receptor binding and anxiety: a [11C] WAY-100635 PET investigation in healthy volunteers","volume":"158","author":"Tauscher","year":"2001","journal-title":"Am. J. Psych."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0107","series-title":"RStudio: Integrated Development For R","author":"Team","year":"2020"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0108","series-title":"R: A language and Environment For Statistical Computing","author":"Team","year":"2021"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0109","series-title":"EndNote","author":"Team","year":"2013"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0110","first-page":"163","article-title":"The association of buspirone and its metabolite 1-pyrimidinylpiperazine in the remission of comorbid anxiety with depressive features and alcohol dependency","volume":"27","author":"Tollefson","year":"1991","journal-title":"Psychopharmacol. Bull"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0111","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4088\/JCP.v58n0405","article-title":"Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study","volume":"58","author":"van Vliet","year":"1997","journal-title":"J. Clin. Psych."},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0113","first-page":"3717","article-title":"The clinical efficacy of tandospirone citrate in treating generalized anxiety disorder","volume":"21","author":"Wang","year":"2014","journal-title":"Zhongguo. Jiceng. Yiyao"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0114","doi-asserted-by":"crossref","first-page":"475","DOI":"10.31887\/DCNS.2011.13.4\/jwemmie","article-title":"Neurobiology of panic and pH chemosensation in the brain","volume":"13","author":"Wemmie","year":"2011","journal-title":"Dialogues. Clin. Neurosci"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0115","first-page":"187","article-title":"A Controlled Study of Tandospirone and Paroxetine in the Treatment of 98 Cases of Generalized Anxiety","volume":"18","author":"Xing","year":"2011","journal-title":"J. Pract. Med. Techniques"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0116","first-page":"20","article-title":"Clinical evaluation of fixed-dose tandospirone in the treatment of social anxiety disorder","volume":"26","author":"Yang","year":"2014","journal-title":"Med. J. Chinese People's Health"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0117","first-page":"35","article-title":"A comparative study of Tandospirone and Clonazepam in the treatment of patients with generalized anxiety disorder","volume":"10","author":"Zhang","year":"2007","journal-title":"Chinese J Practical Nervous Diseases"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0118","first-page":"585","article-title":"A comparative study of citalopram and tandospirone in the treatment of generalized anxiety disorder","volume":"41","author":"Zhang","year":"2012","journal-title":"Shanxi. Yiyao. Zazhi"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0119","first-page":"178","article-title":"Comparative study of tandospirone and alprazolam in treatment of generalized anxiety disorder","volume":"13","author":"Zhao","year":"2010","journal-title":"Shiyong. Yaowu. Yu. Linchuang"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0120","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.euroneuro.2022.01.002","article-title":"Neuroscience-based nomenclature of psychotropics: progress report","volume":"57","author":"Zohar","year":"2022","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2023.07.008_bib0121","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.euroneuro.2015.08.019","article-title":"A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature","volume":"25","author":"Zohar","year":"2015","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X23001396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X23001396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T18:06:46Z","timestamp":1760378806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X23001396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":121,"alternative-id":["S0924977X23001396"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2023.07.008","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy, safety, and adverse events of azapirones in anxiety disorders: A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2023.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}